Lynparza® for the Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Adenocarcinoma of the Pancreas
ASCO GI 2021: Results From the Phase 3 POLO Trial
Cancer Trial Results
Olaparib in Metastatic Pancreatic Cancer
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Cureus | Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer | Article
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer - YouTube
Cancer Trial Results
JNCCN study evaluates cost-effectiveness of o | EurekAlert!
ASCO GI 2021: Results From the Phase 3 POLO Trial
ASCO GI 2021: Results From the Phase 3 POLO Trial
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
Pancreatic cancer treatment: Polo trial for Maintenance Lynparza (olaparib)
Cancer Trial Results
Olaparib now approved for advanced pancreatic cancer - UChicago Medicine
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
